1. Marcello MA, Cunha LL, Batista FA, Ward LS. Obesity and thyroid cancer. Endocr Relat Cancer 2014;21:T255-71.
[CROSSREF] [PUBMED]
2. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013 2013:291546.
[CROSSREF] [PDF]
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
[CROSSREF] [PUBMED]
5. Xu L, Port M, Landi S, Gemignani F, Cipollini M, Elisei R, et al. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid 2014;24:966-74.
[CROSSREF] [PUBMED] [PMC]
6. Han JM, Kim TY, Jeon MJ, Yim JH, Kim WG, Song DE, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013;168:879-86.
[CROSSREF] [PUBMED]
7. Rinaldi S, Lise M, Clavel-Chapelon F, Boutron-Ruault MC, Guillas G, Overvad K, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012;131:E1004-14.
[CROSSREF] [PUBMED]
8. Leitzmann MF, Brenner A, Moore SC, Koebnick C, Park Y, Hollenbeck A, et al. Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer 2010;126:2947-56.
[CROSSREF] [PUBMED] [PMC]
9. Kitahara CM, McCullough ML, Franceschi S, Rinaldi S, Wolk A, Neta G, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 2016;26:306-18.
[CROSSREF] [PUBMED] [PMC]
10. Kwon H, Han KD, Park CY. Weight change is significantly associated with risk of thyroid cancer: a nationwide population-based cohort study. Sci Rep 2019;9:1546.
[CROSSREF] [PUBMED] [PMC] [PDF]
11. Kim WG, Cheng SY. Mechanisms linking obesity and thyroid cancer development and progression in mouse models. Horm Cancer 2018;9:108-16.
[CROSSREF] [PUBMED] [PDF]
12. Pappa T, Alevizaki M. Obesity and thyroid cancer: a clinical update. Thyroid 2014;24:190-9.
[CROSSREF] [PUBMED]
13. Balkan F, Onal ED, Usluogullari A, Tuzun D, Ozdemir D, Inancli SS, et al. Is there any association between insulin resistance and thyroid cancer?: a case control study. Endocrine 2014;45:55-60.
[CROSSREF] [PUBMED] [PDF]
14. Pazaitou-Panayiotou K, Polyzos SA, Mantzoros CS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev 2013;14:1006-22.
[CROSSREF] [PUBMED]
15. Almquist M, Johansen D, Bjorge T, Ulmer H, Lindkvist B, Stocks T, et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control 2011;22:743-51.
[CROSSREF] [PUBMED] [PDF]
16. Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 2009;7:375-80.
[CROSSREF] [PUBMED]
17. Dossus L, Franceschi S, Biessy C, Navionis AS, Travis RC, Weiderpass E, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer 2018;142:1332-42.
[CROSSREF] [PUBMED]
18. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab 2011;96:E2023-8.
[CROSSREF] [PUBMED] [PMC]
19. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 2013;65:203-10.
[CROSSREF] [PUBMED] [PDF]
20. Pazaitou-Panayiotou K, Panagiotou G, Polyzos SA, Mantzoros CS. Serum adiponectin and insulin-like growth factor 1 in predominantly female patients with thyroid cancer: association with the histologic characteristics of the tumor. Endocr Pract 2016;22:68-75.
[CROSSREF] [PUBMED]
21. Abella V, Pino J, Scotece M, Conde J, Lago F, Gonzalez-Gay MA, et al. Progranulin as a biomarker and potential therapeutic agent. Drug Discov Today 2017;22:1557-64.
[CROSSREF] [PUBMED]
22. Matsubara T, Mita A, Minami K, Hosooka T, Kitazawa S, Takahashi K, et al. PGRN is a key adipokine mediating high fat diet-induced insulin resistance and obesity through IL-6 in adipose tissue. Cell Metab 2012;15:38-50.
[CROSSREF] [PUBMED]
23. Koo DH, Park CY, Lee ES, Ro J, Oh SW. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS One 2012;7:e39880.
[CROSSREF] [PUBMED] [PMC]
24. Arechavaleta-Velasco F, Perez-Juarez CE, Gerton GL, Diaz-Cueto L. Progranulin and its biological effects in cancer. Med Oncol 2017;34:194.
[CROSSREF] [PUBMED] [PMC] [PDF]
25. Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, et al. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev 2013;22:1730-5.
[CROSSREF] [PUBMED]
26. Demorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2013;2:145-51.
[PUBMED] [PMC]
27. Tkaczuk KR, Yue B, Zhan M, Tait N, Yarlagadda L, Dai H, et al. Increased circulating level of the survival factor GP88 (progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast Cancer (Auckl) 2011;5:155-62.
[CROSSREF] [PUBMED] [PMC]
28. Edelman MJ, Feliciano J, Yue B, Bejarano P, Ioffe O, Reisman D, et al. GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma. Hum Pathol 2014;45:1893-9.
[CROSSREF] [PUBMED] [PMC]
29. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
30. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med 2014;371:1765-7.
[CROSSREF] [PUBMED]
31. Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516-27.
[CROSSREF] [PUBMED] [PDF]
32. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
[CROSSREF] [PUBMED]
33. Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014;29:217-25.
[CROSSREF] [PUBMED] [PMC]
34. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006;331:166-74.
[CROSSREF] [PUBMED]
35. Han SJ, Boyko EJ. The evidence for an obesity paradox in type 2 diabetes mellitus. Diabetes Metab J 2018;42:179-87.
[CROSSREF] [PUBMED] [PMC]
36. Vigneri R, Malandrino P, Vigneri P. The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 2015;27:1-7.
[CROSSREF] [PUBMED]
37. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78.
[CROSSREF] [PUBMED]
38. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
[CROSSREF] [PUBMED]
39. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:s858-66.
[CROSSREF] [PUBMED] [PDF]
40. Abooshahab R, Yaghmaei P, Ghadaksaz HG, Hedayati M. Lack of association between serum adiponectin/leptin levels and medullary thyroid cancer. Asian Pac J Cancer Prev 2016;17:3861-4.
[PUBMED]